Table 1.
Characteristics of patients with AML
| Characteristic | AML |
|---|---|
| Number of patients | 76 |
| Mean (range) age, year | 45.5 (18–62) |
| Mean (±SD) white blood cell count (G/l) | 32.01 ± 28.04 |
| Mean (range) of the blastic cells in peripheral blood (range) | 49 (0–93) |
| Mean (range) of blastic cells in bone marrow (range) | 55 (20–98) |
| Acute myeloid leukaemia with recurrent genetic abnormalities | n (%) |
| t(8;21) (q22;q22);(AML1/ETO) | 10 (13.1 %) |
| inv(16) (p13;q22) or t(16;16) (p13;q22); (CBFß/ MYH11) | 2 (2.6 %) |
| t(9;11); MLLT3-MLL | 3 (4.0 %) |
| AML with multilineage dysplasia without antecedent MDS | 1 (1.3 %) |
| AML therapy-related | 0 (0.0 %) |
| AML not otherwise categorized | 61 |
| AML, minimally differentiated | 8 (10.5 %) |
| AML without maturation | 13 (17.1 %) |
| AML with maturation | 20 (26.3 %) |
| Acute myelomonocytic leukaemia (AMMoL) | 14 (18.4 %) |
| AMMoL with eosinophilia | 0 (0.0 %) |
| Acute monoblastic leukaemia | 2 (2.6 %) |
| Acute monocytic leukaemia | 2 (2.6 %) |
| Acute erythroid leukaemia | 1 (1.3 %) |
| Acute megakaryoblastic leukaemia | 0 (0.0 %) |
| Outcome of induction therapy, n | |
| CR achieved after first induction | 44 |
| CR achieved after second induction | 12 |
| CR achieved after third induction | 3 |
| Mortality during first/second/third induction/consolidation | 5/5/3/0 |
| Post-consolidation treatment | |
| AlloHSCT | 50 |
| Maintenance | 9 |
| FLT3-ITD/NMP1 mut /CEBPA mut | 13/4/1 |
| Favorable risk | 13 (17.0 %) |
| Intermediate risk I | 17 (22.5 %) |
| Intermediate risk II | 13 (17.0 %) |
| Unfavourable risk | 33 (43.5 %) |
AML acute myeloid leukaemia, CR complete remission, AlloHSCT allogenic haematopoietic stem cell transplantation, NPM1 mut mutated nucleophosmin, CEBPA mut mutated core-binding factor leukaemia, FLT3-ITD internal tandem duplication of Fms-like tyrosine kinase 3